Peiling Yang, PhD

Peiling Yang, PhD is a contributing author on Psychiatrist.com. Peiling Yang has authored or co-authored 8 peer-reviewed articles published across the Journal of Clinical Psychiatry and the Primary Care Companion for CNS Disorders between 2011 and 2015. Their work focuses on Depression (MDD) and Schizophrenia/Schizoaffective Disorders.

Depression (MDD) Schizophrenia/Schizoaffective Disorders

Frequent co-authors

Ni A. Khin Thomas P. Laughren Robert J. Temple Yeh-Fong Chen Ellis F. Unger H. M. James Hung Yang Yang Eiji Ishida

Consensus Statement

Regulatory and Scientific Issues in Studies to Evaluate Sexual Dysfunction in Antidepressant Drug Trials

August 26, 2015

Mitchell V. Mathis, Peiling Yang, Ellis F. Unger, et al

Review Article

Summary of Findings From the FDA Regulatory Science Forum on Measuring Sexual Dysfunction in Depression Trials

August 26, 2015

Peiling Yang, Robert J. Temple, Ni A. Khin, et al

Perspective

The US Food and Drug Administration's Perspective on the New Antidepressant Vortioxetine

November 11, 2014

Jing Zhang, Mitchell V. Mathis, Jenn W. Sellers, et al

Review Article

Review of Maintenance Trials for Major Depressive Disorder: A 25-Year Perspective From the US Food and Drug Administration

March 15, 2014

Peiling Yang, Mitchell Mathis, Thomas P. Laughren, et al

Review Article

Exploratory Analyses of Efficacy Data From Schizophrenia Trials in Support of New Drug Applications Submitted to the US Food and Drug Administration

May 15, 2012

Peiling Yang, Thomas P. Laughren, Ni A. Khin, et al

Letter to the Editor

Reply to Failure Rate and "Professional Subjects" in Clinical Trials of Major Depressive Disorder

September 15, 2011

Peiling Yang, Thomas P. Laughren, Ni A. Khin, et al

Original Research

Vilazodone: Clinical Basis for the US Food and Drug Administration's Approval of a New Antidepressant

September 15, 2011

Peiling Yang, Linda Fossom, Ellis F. Unger, et al

Original Research

Exploratory Analyses of Efficacy Data From Major Depressive Disorder Trials Submitted to the US Food and Drug Administration in Support of New Drug Applications

April 15, 2011

Peiling Yang, Thomas P. Laughren, Ni A. Khin, et al

Peiling Yang, PhD

Frequent co-authors

Regulatory and Scientific Issues in Studies to Evaluate Sexual Dysfunction in Antidepressant Drug Trials

Summary of Findings From the FDA Regulatory Science Forum on Measuring Sexual Dysfunction in Depression Trials

The US Food and Drug Administration's Perspective on the New Antidepressant Vortioxetine

Review of Maintenance Trials for Major Depressive Disorder: A 25-Year Perspective From the US Food and Drug Administration

Exploratory Analyses of Efficacy Data From Schizophrenia Trials in Support of New Drug Applications Submitted to the US Food and Drug Administration

Reply to Failure Rate and "Professional Subjects" in Clinical Trials of Major Depressive Disorder

Vilazodone: Clinical Basis for the US Food and Drug Administration's Approval of a New Antidepressant

Exploratory Analyses of Efficacy Data From Major Depressive Disorder Trials Submitted to the US Food and Drug Administration in Support of New Drug Applications

ELSEWHERE:

FOLLOW US:

Peiling Yang, PhD

Frequent co-authors

Regulatory and Scientific Issues in Studies to Evaluate Sexual Dysfunction in Antidepressant Drug Trials

Summary of Findings From the FDA Regulatory Science Forum on Measuring Sexual Dysfunction in Depression Trials

The US Food and Drug Administration's Perspective on the New Antidepressant Vortioxetine

Review of Maintenance Trials for Major Depressive Disorder: A 25-Year Perspective From the US Food and Drug Administration

Exploratory Analyses of Efficacy Data From Schizophrenia Trials in Support of New Drug Applications Submitted to the US Food and Drug Administration

Reply to Failure Rate and "Professional Subjects" in Clinical Trials of Major Depressive Disorder

Vilazodone: Clinical Basis for the US Food and Drug Administration's Approval of a New Antidepressant

Exploratory Analyses of Efficacy Data From Major Depressive Disorder Trials Submitted to the US Food and Drug Administration in Support of New Drug Applications

Live Webinar and Q&A With Dr Deligiannidis

Subscribe to readmore articles

Live Webinar
and Q&A With
Dr Deligiannidis

Subscribe to read
more articles